NCT01876823View on ClinicalTrials.gov

Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Mild Cognitive ImpairmentMajor Depressive DisorderAlzheimer's Disease
Interventions
DRUG

es-citalopram

es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.

DRUG

Memantine

After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

All Listed Sponsors
lead

New York State Psychiatric Institute

OTHER

NCT01876823 - Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment | Biotech Hunter | Biotech Hunter